A glicosamina-6-fosfato sintase (GlmS) catalisa a formação de glicosamina-6-fosfato a partir de frutose-6-fosfato. Esta é a primeira etapa da via biossintética de aminoaçúcares, componentes estruturais importantes da parede celular de fungos e bactérias. Este trabalho descreve o planejamento, a síntese e a avaliação da atividade inibitória da GlmS de dois novos compostos aromáticos enantioméricos, análogos de 2-amino-2-desoxi-D-glucitol-6-fosfato (ADGP) e de seu epímero 2-amino-2-desoxi-D-manitol-6-fosfato (ADMP), dois importantes inibidores da GlmS. Os análogos aromáticos apresentaram atividade inibitória modesta, na faixa de mmol L -1 .
Introduction
Systemic fungi infections remain a problem in modern chemotherapy. Current therapeutic arsenal does not fulfill all medical needs. The increasing number of immunocompromised patients, due to anticancer chemotherapy, organ transplantation and AIDS, along with drug resistance, makes things more complicated. 1, 2 Thus the search for new antifungal agents is mandatory. Glucosamine-6-phosphate synthase (GlmS) catalyses the transformation of D-fructose-6-phosphate (Fru-6P) into D-glucosamine-6-phosphate (GlcN-6P). This is, in turn, converted into UDP-GlcNAc, the nucleotide form of N-acetylglucosamine that is the building block for the biosynthesis of chitin. 3, 4 The enzyme has been validated as a new target for the development of new antifungal agents. 4, 5 GlmS has two catalytic domains, namely, a glutaminase and an isomerase domains. The glutaminase domain is responsible for the hydrolysis of glutamine and generation of ammonia and glutamate. The ammonia released travels across a hydrophobic tunnel to reach the isomerase domain, where it is transferred to enzyme-bound Fru-6P. 6, 7 Several inhibitors of both domains have been reported. [8] [9] [10] [11] Inhibitors of the glutaminase domain are L-glutamine mimics whereas inhibitors of the isomerase domain have been trying to mimic the putative transition state intermediates. 4 Therefore 2-amino-2-deoxy-Dglucitol-6-phosphate (ADGP) and 2-amino-2-deoxy-Dmanitol-6-phosphate (ADMP) are, along with D-arabinoseoxime-6-phosphate, the most potent inhibitors described thus far. 9, 10 Nevertheless, these compounds possess weak in vitro antifungal activity which was attributed to low cell penetration due to the high hydrophilic character of these compounds. 12 Lipophilic derivatives of ADGP were prepared and some of them did display enhanced in vitro activity, 11 reinforcing the importance of hydrophilic/ lipophilic balance for good activity.
The replacement of carbohydrate moieties of bioactive compounds by an aromatic ring has been a useful strategy for the obtention of active analogs. 13 Besides increasing the lipophilic character, the ring introduces conformational restriction, which might eventually enhances activity by selecting the bioactive conformation. The 6-phosphate and 2-amino groups of ADGP have been suggested as crucial for its enzyme inhibitory potency. 11 Substitution of the C3-C6 backbone chain by a meta phenyloxy ring linking the two groups was envisaged as one possibility for aromatic introduction. This was supported by molecular modeling (docking) which points out a similar distance between C2 and O6 atoms in the two molecules (5.3 Å for ADGP vs 5.7 Å for 2), and the good fitting for some of the aromatic molecule conformers with the crystallographic structure of ADGP in the active site of GlmS (E. coli) (Figure 1 ).
With this in mind we planned the synthesis of compounds 1 and 2, according to the retrosynthetic analysis shown in Figure 2 .
The synthesis of 1 and 2 were then carried out according to the synthetic route shown in Figure 3 .
Results and Discussion
Initially, the commercially available protected serine 3 was reacted with LiBH 4 in THF/CH 3 OH at -10 o C to give the alcohol 4.
14 Reaction of 4 with 3-benzoyloxyphenol under Mitsunobu conditions 15 at 80 °C afforded the corresponding ether 5. Removal of the benzoyl protecting group was achieved upon treatment with CH 3 ONa in CH 3 OH at 0 °C to afford 6 in high yield. Phosphorylation with dibenzylphosphite (HPO(BnO) 2 ), in the presence of NaOH and CBr 4 , 16 gave the aromatic phosphate 7 in 90% yield. Hydrogenolysis of the benzyl phosphate (H 2 , Pd-C, Parr hydrogenator, 40 psi) and subsequent removal of N-Boc and dimethyl acetal groups with TFA 17 followed by preparative HPLC purification gave the target compounds 1S or 2R, in 19% and 30% overall yield, respectively. Inhibitory assay against GlmS from E. coli was performed according to published procedures. 18 Results are given in Table 1 .
As shown in Table 1 , compounds 1 and 2 were poor inhibitors of GlmS, displaying IC 50 in the millimolar range. Although the replacement of the hydroxyl groups in ADGP and ADMP by an aromatic ring can provide higher lipophilicity to the resulting analogs, as predict by ACD 
Conclusions
In conclusion, we reported the design, synthesis and evaluation of two chiral aromatic analogs of the GlmS inhibitors ADGP and ADMP. Although the target compounds displayed weak inhibitory activity, they represent a new class of Glms inhibitors whose activity can be improved by further modification. This is in progress and will be reported in due time.
Experimental

General procedures
The reactions were monitored by thin-layer chromatography (TLC) performed on silica gel 60 F254 (Merck®). Melting points were determined with a Microquímica MQAPF 301 apparatus and are uncorrected. Flash chromatography was performed on silica gel 230-600 mesh (Merck®). NMR spectrum was recorded on a Bruker AC300 or AC500 spectrometer at ambient temperature or under heating at 363K. Chemical shifts (d) were reported in ppm and standardized to the residual undeuterated solvents as the reference peaks and coupling constants (J) in Hz. The products 1S and 2R were purified on Atlantis® Prep dC 18 OBD preparative column (19 mm × 150 mm, 5 µm) using an HPLC apparatus (Waters) equipped with a photodiode array detector. Gradient elution was employed using solvent A (10 mmol L -1 NH 4 OAc), solvent B (CH 3 CN); gradient: 0-7 min 100% A; 7-9 min linear change to A-B (40:60); 9-30 min, isocratic elution with 60% B (column rinsing); 30-50 min 100% A (column equilibration). The flow rate was kept at 
Synthesis of (R)-tert-butyl 4-((3-(benzoyloxy)phenoxy) methyl)-2,2-dimethyl-oxazolidine-3-carboxylate 5R
Diethyl azodicarboxylate (0.20 mL, 1.20 mmol) was added to a mixture of 3-benzoyloxyphenol (0. 
Synthesis of (S)-tert-butyl 4-((3-(benzoyloxy)phenoxy) methyl)-2,2-dimethyl-oxazolidine-3-carboxylate 5S
The S enantiomer was prepared following the same procedure described above to prepare 5R (0.21 g, 0.9 mmol) to give 5S (0.29 g, 76% 
Synthesis of (R)-tert-butyl 4-((3-hydroxyphenoxy)methyl)-2,2-dimethyloxazolidine-3-carboxylate 6R
To a solution of 5R (0.19 g, 0.44 mmol) in dry CH 3 OH (3 mL), was added CH 3 ONa (24 mg, 0.44 mmol) at 0 °C. After 30 min. the solvent was removed under reduced pressure. The residue was purified by flash chromatography on silica gel (n-hexane/ AcOEt 8:2) to give pure 6R as a white solid, (0.14 g; 95% 
Synthesis of (S)-tert-butyl 4-((3-hydroxyphenoxy)methyl)-2,2-dimethyloxazolidine-3-carboxylate 6S
The S enantiomer was prepared following the same procedure described above to prepare 6R (0.18 g, 0.42 mmol) to give pure phenol 6S (0.12 g, 85% C NMR spectra, as for 6R.
Synthesis of (R)-tert-butyl 4-((3-(bis(benzyloxy) phosphoryloxy)phenoxy)methyl)-2,2-dimethyloxazolidine-3-carboxylate 7R
A solution of dibenzylphosphite (0.12 g, 0.46 mmol) and phenol 6R (0.10 g, 0.31 mmol) in CH 2 Cl 2 (2 mL) was added to an ice-cold two-phase system consisting of CBr 4 (0.053 g, 0.16 mmol), 30% (m/v) aqueous NaOH (100 µL), H 2 0 (1 mL) and CH 2 Cl 2 (1 mL). The system was stirring for 30 min at room temperature. CH 2 Cl 2 (10 mL) was added and the organic layer was separated, washed with H 2 O (3 × 5 mL), dried over MgSO 4 and filtrated. Concentration followed by flash chromatography on silica gel of the crude material afforded the product 7R (0. 17 
Synthesis of (S)-tert-butyl 4-((3-(bis(benzyloxy) phosphoryloxy)phenoxy)methyl)-2,2-dimethyloxazolidine-3-carboxylate 7S
The S enantiomer was prepared following the same procedure described above to prepare 7R (0.12 g, 0.37 mmol) to give 7S (0.15g, 76% yield 
Synthesis of 3-(2-(S)-amino-3-hydroxypropoxy)phenyl dihydrogenphosphate 1
A solution of dibenzylphosphate 7R (0.16 g, 0.27 mmol) in THF (2 mL) was hydrogenolyzed under hydrogen pressure (40 psi) in presence of 10% activated Pd-C (40 mg) at room temperature for 1h. The reaction mixture was filtered and the THF evaporated under vacuum. TFA (1 mL) was then added to a solution of the residue in CH 3 OH (2 mL). The reaction mixture was stirred at room temperature for 3h. TFA was eliminated by co-distillation with CH 2 Cl 2 and CH 3 
Synthesis of 3-(2-(R)-amino-3-hydroxypropoxy)phenyl dihydrogenphosphate 2
The R enantiomer was prepared following the same procedure using 7S (0.13g, 0.22 mmol) to give the desired phosphate 2R (39 mg; 68% yield). mp 163. 
Determination of enzyme activity
GlmS was purified to homogeneity using a protocol adapted from the procedure first reported by Badet and co-workers. 20 GlmS activity was spectrophotometrically assayed using the modified microplate Morgan-Elson method. 18 The assay mixture contained, in a final volume of 100 µL for each well of the microplate, 100 mmol L . Following preincubation at 37 °C for 10 min, the enzymatic reaction was initiated by the addition of 0.06 unit of GlmS. Precisely 30 min later (initial rate conditions), the reaction was stopped by the addition of 10 µL of a 1.5% (v/v) acetic anhydride solution in acetone (prepared daily) followed by 50 µL of a 0.2 mol L -1 borate solution. After being heated to 80 °C for 30 min, the microplate (containing the various reaction mixtures) was centrifuged before addition of 130 µL of Ehrlich reagent (10% (m/v) solution of p-dimethyl-aminobenzaldehyde in acetic acid/ concentrated HCl mixture (87/13; v/v) to each well. Then, the amount of GlcN-6P formed was measured from the absorbance of the Ehrlich adduct at 585 nm (e value was determined daily from a GlcN-6P standard solution). The initial rate of formation of Glc-N6P as a function of the inhibitor concentration allowed the determination of the IC 50 value (inhibition that gives an initial rate equal to 50% of the rate in the absence of inhibitor).
Molecular modeling
The tridimensional structures of compounds 1 and 2 were constructed using Corina v3.44. Docking studies were performed on the dimer structure of GlmS (PDB code 2J6H) 21 with Gold 4.0, 22 using the default parameters and the GoldScore scoring function. A number of five water molecules (W166, W251, W254, W256, W257), which are conserved in all GlmS structures, were considered in the docking procedure. Ligand 2-deoxy-2-amino-D-glucitol-6-phosphate (ADGP) from the structure 1MOS 23 was used as reference in the docking analysis. Raytraced image was produced with UCSF Chimera 24 and POV-Ray. 
